{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:20:20Z","timestamp":1787635220576,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01201-1","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:51:07Z","timestamp":1787575867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple and quadruple combination antihypertensive therapy in untreated individuals"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-6738","authenticated-orcid":false,"given":"Phidias","family":"Rueter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-1896","authenticated-orcid":false,"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-7936","authenticated-orcid":false,"given":"Abdul","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"1201_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441\u201350.","journal-title":"Circulation"},{"key":"1201_CR2","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.2020.14545","volume":"324","author":"P Muntner","year":"2020","unstructured":"Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. Jama. 2020;324:1190\u2013200.","journal-title":"Jama"},{"key":"1201_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5694\/mja2.52373","volume":"221","author":"AE Schutte","year":"2024","unstructured":"Schutte AE, Bennett B, Chow CK, Cloud GC, Doyle K, Girdis Z, et al. National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030. Med J Aust. 2024;221:126\u201334.","journal-title":"Med J Aust"},{"key":"1201_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/ajh\/hpae141","volume":"38","author":"ST Hardy","year":"2025","unstructured":"Hardy ST, Jaeger BC, Foti K, Ghazi L, Wozniak G, Muntner P. Trends in Blood Pressure Control among US Adults With Hypertension, 2013-2014 to 2021-2023. Am J Hypertens. 2025;38:120\u20138.","journal-title":"Am J Hypertens"},{"key":"1201_CR5","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Hypertension. 2025;82:e212\u2013e316.","journal-title":"Hypertension"},{"key":"1201_CR6","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"1201_CR7","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1097\/HJH.0000000000002096","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37:1768\u201374.","journal-title":"J Hypertens"},{"key":"1201_CR8","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/pds.4884","volume":"28","author":"K Marinier","year":"2019","unstructured":"Marinier K, Macouillard P, de Champvallins M, Deltour N, Poulter N, Mancia G. Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2019;28:1572\u201382.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1201_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","volume":"135","author":"LS Phillips","year":"2001","unstructured":"Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135:825\u201334.","journal-title":"Ann Intern Med"},{"key":"1201_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","volume":"72","author":"F Rea","year":"2018","unstructured":"Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72:846\u201353.","journal-title":"Hypertension"},{"key":"1201_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034787","volume":"14","author":"JT Mohl","year":"2025","unstructured":"Mohl JT, Moreno CA, Sadik K, Singhal M, Rooney A, Ciemins EL. Evaluation of blood pressure control, medication adherence, and therapeutic inertia in US patients with hypertension prescribed multiple antihypertensives. J Am Heart Assoc. 2025;14:e034787.","journal-title":"J Am Heart Assoc"},{"key":"1201_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/ajh\/hpad108","volume":"37","author":"GT Hiura","year":"2024","unstructured":"Hiura GT, Markossian TW, Probst BD, Tootooni MS, Wozniak G, Rakotz M, et al. Age and comorbidities are associated with therapeutic inertia among older adults with uncontrolled blood pressure. Am J Hypertens. 2024;37:280\u20139.","journal-title":"Am J Hypertens"},{"key":"1201_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","volume":"5","author":"N Wang","year":"2020","unstructured":"Wang N, Salam A, Webster R, de Silva A, Guggilla R, Stepien S, et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial. JAMA Cardiol. 2020;5:1219\u201326.","journal-title":"JAMA Cardiol"},{"key":"1201_CR14","first-page":"1087","volume":"81","author":"N Wang","year":"2024","unstructured":"Wang N, Von Huben A, Marschner S, Nelson MR, Nolde JM, Schlaich MP, et al. Therapeutic inertia with initial low-dose quadruple combination therapy for hypertension: results from the QUARTET Trial. Hypertension. 2024;81:1087\u201394.","journal-title":"Hypertension"},{"key":"1201_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Rueter P, Atkins E, Webster R, Huffman M, de Silva A, et al. Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis. JAMA Cardiol. 2023;8:606\u201311.","journal-title":"JAMA Cardiol"},{"key":"1201_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101883","volume":"4","author":"N Wang","year":"2025","unstructured":"Wang N, Rueter P, Salam A, Huffman MD, Atkins E, Ojji D, et al. Low-Dose combinations with 3 or 4 blood pressure-lowering medications for the treatment of hypertension. JACC Adv. 2025;4:101883.","journal-title":"JACC Adv"},{"key":"1201_CR17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Bmj. 2003;326:1427.","journal-title":"Bmj"},{"key":"1201_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0140-6736(25)00991-2","volume":"406","author":"N Wang","year":"2025","unstructured":"Wang N, Salam A, Pant R, Kumar A, Dhurjati R, Haghdoost F, et al. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Lancet. 2025;406:915\u201325.","journal-title":"Lancet"},{"key":"1201_CR19","doi-asserted-by":"crossref","unstructured":"An J, Zhou H, Ni L, Juan R, Portugal C, Romero DI, et al. Trends in initial combination antihypertensive therapy in a US health system. Am J Hypertens. 2025.","DOI":"10.1093\/ajh\/hpaf248"},{"key":"1201_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jamacardio.2024.5124","volume":"10","author":"H Mapesi","year":"2025","unstructured":"Mapesi H, Rohacek M, Vanobberghen F, Gupta R, Wilson HI, Lukau B, et al. Treatment strategies to control blood pressure in people with hypertension in Tanzania and Lesotho: a randomized clinical trial. JAMA Cardiol. 2025;10:321\u201333.","journal-title":"JAMA Cardiol"},{"key":"1201_CR21","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","volume":"404","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404:1536\u201346.","journal-title":"Lancet"},{"key":"1201_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2024.18080","volume":"332","author":"DB Ojji","year":"2024","unstructured":"Ojji DB, Salam A, Sani MU, Ogah OS, Schutte AE, Huffman MD, et al. Low-Dose triple-pill vs standard-care protocols for hypertension treatment in nigeria: a randomized clinical trial. Jama. 2024;332:1070\u20139.","journal-title":"Jama"},{"key":"1201_CR23","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.jacc.2024.08.025","volume":"84","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination compared with placebo for initial treatment of hypertension. J Am Coll Cardiol. 2024;84:2393\u2013403.","journal-title":"J Am Coll Cardiol"},{"key":"1201_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: A randomized clinical trial. Jama. 2018;320:566\u201379.","journal-title":"Jama"},{"key":"1201_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1630732","volume":"16","author":"C Carcel","year":"2025","unstructured":"Carcel C, Haghdoost F, Davies L, Cordato D, Griffiths L, Balicki G, et al. Blood pressure lowering for prevention of episodic migraine: results of a pilot randomized, placebo-controlled trial of combination blood pressure lowering medication with propranolol. Front Neurol. 2025;16:1630732.","journal-title":"Front Neurol"},{"key":"1201_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","volume":"389","author":"CK Chow","year":"2017","unstructured":"Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389:1035\u201342.","journal-title":"Lancet"},{"key":"1201_CR27","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.2147\/DDDT.S286586","volume":"14","author":"SJ Hong","year":"2020","unstructured":"Hong SJ, Sung KC, Lim SW, Kim SY, Kim W, Shin J, et al. Low-Dose triple antihypertensive combination therapy in patients with hypertension: a randomized, double-blind, phase II study. Drug Des Devel Ther. 2020;14:5735\u201346.","journal-title":"Drug Des Devel Ther"},{"key":"1201_CR28","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jacc.2025.12.028","volume":"87","author":"KC Sung","year":"2026","unstructured":"Sung KC, Park K, Kim DH, Lim SW, Hong SJ, Lee JB, et al. Single-Pill low-dose triple combination therapy vs standard-dose monotherapy in patients with mild-to-moderate hypertension. J Am Coll Cardiol. 2026;87:2392\u2013411.","journal-title":"J Am Coll Cardiol"},{"key":"1201_CR29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jch.14570","volume":"24","author":"KC Sung","year":"2022","unstructured":"Sung KC, Sung JH, Cho EJ, Ahn JC, Han SH, Kim W, et al. Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. J Clin Hypertens (Greenwich). 2022;24:1298\u2013309.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1201_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","volume":"49","author":"A Mahmud","year":"2007","unstructured":"Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents\u2013a preliminary report. Hypertension. 2007;49:272\u20135.","journal-title":"Hypertension"},{"key":"1201_CR31","unstructured":"Australian and New Zealand Clinical Trials Registry; 2017 - Identifier ACTRN12617001323314. Pilot phase for the Tension-type HeadAche Prevention Project (HAPPy Too) to investigate in a double- blind, randomised trial whether treatment with low-dose blood pressure (BP) lowering therapy on top of standard care will reduce tension-type headache compared to placebo and standard care. Accessed September 2024. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=373518."},{"key":"1201_CR32","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.jacc.2025.08.063","volume":"86","author":"N Wang","year":"2025","unstructured":"Wang N, Rodgers A. Treating with the goal in mind: the role of low-dose combinations. J Am Coll Cardiol. 2025;86:1492\u20134.","journal-title":"J Am Coll Cardiol."},{"key":"1201_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026582","volume":"11","author":"EKP Lee","year":"2022","unstructured":"Lee EKP, Poon P, Yip BHK, Bo Y, Zhu MT, Yu CP, et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 Million patients. J Am Heart Assoc. 2022;11:e026582.","journal-title":"J Am Heart Assoc"},{"key":"1201_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/jch.14788","volume":"26","author":"YE Dean","year":"2024","unstructured":"Dean YE, Motawea KR, Shebl MA, Elawady SS, Nuhu K, Abuzuaiter B, et al. Adherence to antihypertensives in the United States: A comparative meta-analysis of 23 million patients. J Clin Hypertens (Greenwich). 2024;26:303\u201313.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1201_CR35","doi-asserted-by":"crossref","unstructured":"Reith C, Blackwell L, Emberson JR, Preiss D, Spata E, Davies K, et al. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. The Lancet. 2026;407:689\u2013703.","DOI":"10.1016\/S0140-6736(26)01147-5"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01201-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01201-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01201-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:02:55Z","timestamp":1787634175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01201-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":35,"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01201-1","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional: George Institute Ventures, the social enterprise arm of The George Institute for Global Health, has received investment to develop fixed-dose combination products, including combinations of blood pressure lowering drugs. The George Institute holds patents in relation to low-dose combination products for the treatment of hypertension and diabetes, of which Professor Rodgers is an inventor. All staff employed by The George Institute have an institutional interest to declare with respect to George Institute Ventures. None of The George Institute staff have a financial interest in these investments or patents. Dr Nelson Wang is supported by the Heart Foundation Post-doctoral Fellowship 108288-2024_PDF.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}